Account Executive - MI Clarity - Texoma Caris Life SciencesAccount Executive - MI Clarity - TexomaTexasThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Georgia Caris Life SciencesAccount Executive - MI Clarity - GeorgiaGeorgiaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Pacific Northwest Caris Life SciencesAccount Executive - MI Clarity - Pacific NorthwestWashingtonThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - California South Caris Life SciencesAccount Executive - MI Clarity - California SouthCaliforniaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Rocky Midwest Caris Life SciencesAccount Executive - MI Clarity - Rocky MidwestColoradoThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Central US Caris Life SciencesAccount Executive - MI Clarity - Central USKansasThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Arkansas-Louisiana-Texas Caris Life SciencesAccount Executive - MI Clarity - Arkansas-Louisiana-TexasTexasThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Los Angeles-Hawaii Caris Life SciencesAccount Executive - MI Clarity - Los Angeles-HawaiiCaliforniaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Field Reimbursement Manager Syneos - Commercial - ProdField Reimbursement ManagerDetroit, MIThe FRM will need to collaborate cross functionally with Field Sales, Marketing, Market Access, Public Affairs, State and Government Affairs, Trade and Specialty Pharmacy Accounts while abiding by all corporate and industry policy and procedures. The Field Reimbursement Manager (FRM) will operate as the subject-matter expert on reimbursement, access, and coverage issues affecting the client’s products.
Account Executive - MI Clarity - Boroughs-New Jersey North Caris Life SciencesAccount Executive - MI Clarity - Boroughs-New Jersey NorthNew York, New York$125,000–$145,000 / yearThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Indiana-Michigan Caris Life SciencesAccount Executive - MI Clarity - Indiana-MichiganIndianaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Specialty Account Manager - IVIG CSI PharmacySpecialty Account Manager - IVIGAustin, TexasCommitted to improving the health and livelihood of our patients, our Specialty Account Manager will partner with our extraordinary team of Pharmacists, Clinicians, and Business Professionals to bring the highest quality treatments, care, and comfort to the patients we serve. Develops territory routing plan and updates regularly to obtain optimal efficiency in servicing customer needs and marketing to new business/customers.
Account Executive - MI Clarity - Philadelphia-New Jersey South Caris Life SciencesAccount Executive - MI Clarity - Philadelphia-New Jersey SouthNew JerseyThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Central North Caris Life SciencesAccount Executive - MI Clarity - Central NorthIllinoisThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Virginias Caris Life SciencesAccount Executive - MI Clarity - VirginiasVirginiaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - North Carolina Caris Life SciencesAccount Executive - MI Clarity - North CarolinaSouth CarolinaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - New England Caris Life SciencesAccount Executive - MI Clarity - New EnglandConnecticutThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Miami-Puerto Rico Caris Life SciencesAccount Executive - MI Clarity - Miami-Puerto RicoFloridaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Alabama-Mississippi Caris Life SciencesAccount Executive - MI Clarity - Alabama-MississippiAlabamaThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.
Account Executive - MI Clarity - Ohio-Pittsburgh Caris Life SciencesAccount Executive - MI Clarity - Ohio-PittsburghOhioThe Account Executive – MI Clarity is responsible for driving awareness, adoption, and utilization of MI Clarity, an AI-powered prognostic assay designed to assess both early and late distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Educate healthcare providers and care teams on the clinical utility, prognostic value, and evidence supporting MI Clarity, including its ability to identify both early and late distant recurrence risk in eligible breast cancer patients.